Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Genitourinary 1Breast 1

Conditions

Breast Neoplasms 3135Triple Negative Breast Neoplasms 514Ovarian Neoplasms 231Colorectal Neoplasms 189Carcinoma, Non-Small-Cell Lung 189Prostatic Neoplasms 183Neoplasms 175Lung Neoplasms 167Neoplasm Metastasis 165Melanoma 119Stomach Neoplasms 115Pancreatic Neoplasms 113Endometrial Neoplasms 108Uterine Cervical Neoplasms 94Squamous Cell Carcinoma of Head and Neck 87Colonic Neoplasms 82Carcinoma, Intraductal, Noninfiltrating 82Head and Neck Neoplasms 81Sarcoma 62Carcinoma, Renal Cell 62Breast Carcinoma In Situ 62Urinary Bladder Neoplasms 60Motor Activity 59Esophageal Neoplasms 59Brain Neoplasms 51Lymphedema 44Breast Cancer Female 41Liver Neoplasms 39Advanced Breast Cancer 38Lymphoma 37

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fanconi Anemia, Complementation Group D1 × Breast × 1 year × Clear all
NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

Beth Israel Deaconess Medical Center

Phase 2 Active not recruiting
114 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡